Europe OKs Merck Serono's prefilled IVF pen injector

By many accounts, the future of drug delivery belongs to the prefilled syringe. They're secure, easy to use and minimize the chance for dosage error. But it's compliance that Merck Serono has in mind for its prefilled pen injectors meant for fertility-treatment drugs. The company has received approval from the European Commission for three prefilled, ready-to-use pen injectors.

Receiving the European OK are Gonal-F (follitropin alfa), Luveris (lutropin alfa) and Ovitrelle (choriogonadotropin alfa). All three products are recombinant gonadotropins used in fertility treatments, reports in-PharmaTechnologist.com.

"Fertility treatment specialists were involved from the beginning in the development of the new devices for the Merck Serono gonadotropins portfolio for fertility treatment," Merck Serono's Bharat Tewarie said in a statement. "We are pleased to introduce today the specially designed injection devices that combine key features recommended by them."

The pens tell the users whether a complete dose was injected or indicate how much is missing if the dose was incomplete, the company said. Its prefilled pens have also already been approved in Australia, New Zealand, Canada and Switzerland.

- read the story on in-PharmaTechnologist.com
- or read the release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.